How should skin sensitivity be evaluated and managed in a patient taking a GLP‑1 receptor agonist (e.g., exenatide, liraglutide, semaglutide, dulaglutide, tirzepatide)?

GLP-1 Agonist and Skin Sensitivity

Skin sensitivity reactions to GLP-1 receptor agonists are uncommon but documented adverse events that require immediate discontinuation of the offending agent, with the option to trial an alternative GLP-1 RA after confirming drug-specific hypersensitivity through intradermal testing.

Recognition and Clinical Presentation

Skin sensitivity reactions to GLP-1 receptor agonists manifest in several distinct patterns:

• Injection site reactions: Occur in <1% of patients, typically mild and self-limiting 1
• Hypersensitivity reactions: Including anaphylaxis, angioedema, and dermatologic eruptions 2, 3
• Dysesthesia/allodynia: Emerging pattern of burning skin sensations or skin tenderness, particularly with semaglutide and tirzepatide at higher doses 4, 5
• Dermal hypersensitivity: Maculopapular erythema, pruritus, subepidermal blistering with eosinophils 6

The most critical distinction is between local injection site reactions (which may resolve with continued use) and systemic hypersensitivity reactions (which mandate immediate discontinuation).

Immediate Management Algorithm

If Injection Site Reaction Only:

• Continue medication with slow titration to mitigate symptoms 7
• Rotate injection sites systematically 8
• Avoid injecting cold medication 8
• Monitor for progression to systemic symptoms

If Systemic Hypersensitivity (angioedema, urticaria, anaphylaxis):

1. Discontinue the GLP-1 RA immediately 2, 3
2. Treat per standard hypersensitivity protocols (antihistamines, corticosteroids, epinephrine if anaphylaxis)
3. Monitor until complete symptom resolution
4. Do not rechallenge with the same agent 2

If Dysesthesia/Allodynia (burning sensation, skin tenderness):

• Occurs predominantly with semaglutide 2.4 mg and tirzepatide at higher doses 4, 5
• Dose-dependent phenomenon, more common with potent GLP-1 RAs 4
• Options: discontinue (symptoms resolve in most cases) or continue with monitoring (some patients experience spontaneous resolution after 4 months) 5

Cross-Reactivity and Alternative Agent Selection

GLP-1 receptor agonists are NOT universally cross-reactive—patients with hypersensitivity to one agent may tolerate another within the class 9, 6.

Evaluation Protocol for Alternative Agent:

1. Perform intradermal testing to the suspected agent (1:10 dilution) to confirm drug-specific hypersensitivity 9
2. Perform intradermal testing to alternative GLP-1 RA candidates 9
3. If intradermal testing negative to alternative agent, conduct supervised subcutaneous challenge 9
4. If challenge tolerated, clear for initiation under specialist oversight 9

Agent-specific considerations based on safety profiles 10:

• Semaglutide: Higher disproportionate reporting for alopecia and hormonal imbalances
• Dulaglutide and tirzepatide: Lower reporting odds for reproductive/endocrine adverse events
• Liraglutide: Higher risk of any adverse events and discontinuation due to adverse events

Specific Contraindications and Warnings

Absolute contraindications 2, 3:

• Previous serious hypersensitivity reaction to the specific GLP-1 RA or its components
• Personal or family history of medullary thyroid carcinoma (for longer-acting agents: semaglutide, liraglutide, dulaglutide, exenatide ER)
• Multiple endocrine neoplasia type 2

Use caution 2:

• History of angioedema or anaphylaxis with another GLP-1 RA (unknown if predisposes to reactions with different agent)
• Patients with severe gastrointestinal disease
• Renal impairment (monitor for dehydration-related complications)

Monitoring Strategy

At Initiation and Each Dose Escalation:

• Educate patients on signs of hypersensitivity: rash, pruritus, angioedema, respiratory symptoms 7
• Instruct patients to report unusual skin sensations (burning, tenderness) immediately 4, 5
• Examine injection sites for lipohypertrophy or nodules (reported with once-weekly exenatide and semaglutide) 8

Ongoing Surveillance:

• Regular visual inspection and palpation of injection sites 8
• Systematic site rotation documentation to prevent lipodystrophy 8
• Monitor for delayed hypersensitivity reactions (can occur months after initiation) 6

Common Pitfalls

Do not assume all skin reactions are benign injection site reactions—systemic hypersensitivity requires immediate discontinuation, not dose adjustment 2, 3.

Do not assume cross-reactivity—intradermal testing and supervised challenge can identify safe alternatives within the GLP-1 RA class 9.

Do not overlook dysesthesia as a dose-dependent adverse effect—this emerging pattern appears more common with higher-potency agents at maximum doses and may resolve spontaneously or require discontinuation 4, 5.

Do not restart the same agent after confirmed hypersensitivity—this is explicitly contraindicated in FDA labeling 2, 3.